April 24th 2024
The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Available Systemic Therapy Options for Patients with MMR-Proficient Metastatic Endometrial Cancer
January 19th 2023An expert details the currently available systemic therapies for patients with MMR-proficient metastatic endometrial cancer who experienced recurrent disease after platinum-based chemotherapy.
Watch
Dostarlimab Achieves Significant PFS Improvement in Primary Advanced or Recurrent Endometrial Cancer
December 2nd 2022The phase 2 RUBY clinical trial has met its primary end point with dostarlimab-gxly given after chemotherapy achieving progression-free survival improvement in adult patients with primary advanced or recurrent endometrial cancer.
Read More
Results of the ENPAC Trial Shows Promise in Recurrent Endometroid Cancer
November 1st 2022Shannon N. Westin, MD, MPH, discusses the promising results of the ENPAC trial that showed the effectiveness of adding enzalutamide to standard of care chemotherapy for patients with recurrent endometriod cancer.
Watch
Pembrolizumab and Lenvatinib Approval Opens New Door in Endometrial Cancer Treatment
October 12th 2022Wesley Burkett, MD, adiscusses his excitement for the approval of pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.
Watch
Recurrent Metastatic EC: Common Immune-Related Adverse Events And Patient Discussions
September 26th 2022Bhavana Pothuri, MD provides a perspective on the management of immune-related adverse events that can be seen in patients treated for recurrent metastatic endometrial cancer, as well as a focused discussion on the conversations she has with her patients.
Watch
Pembrolizumab Continues to Show Robust Antitumor Activity in MSI-H/dMMR Endometrial Cancer
September 16th 2022Robust and durable antitumor activity continues to be shown with pembrolizumab in patients with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.
Read More
Lenvatinib/Pembrolizumab Benefit Maintained in Advanced Endometrial Cancer
September 11th 2022After extended follow-up, continued benefit was seen with the combination of lenvatinib and pembrolizumab in patients with advanced endometrial cancer who previously received platinum chemotherapy, updated efficacy and safety findings from the phase 3 Study 309/KEYNOTE-775 trial showed.
Read More